HLA-A24-binding KIF-derived peptide

Details HLA-A24-binding KIF-derived peptide HLA-A24-binding KIF-derived peptide

2011-06-28

2011-06-28

Rawlings, Stephen (Department: 1643)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C530S328000, C514S015800, C424S277100, C424S093100, C435S372000

Reexamination Certificate

active

07968098

ABSTRACT:
An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.

REFERENCES:
patent: 03/037917 (2003-05-01), None
patent: 2004/018680 (2004-03-01), None
S. Shichijo et al., “A unique gene having homology with the kinesin family member 18A encodes a tumour-associated antigen recognised by cytotoxic T lymphocytes from HLA-A2+ colon cancer patients”, European Journal of Cancer, vol. 41, pp. 1323-1330, 2005.
M. Harada et al., “Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+glioma patients”, Oncology Reports, vol. 17, pp. 629-636, 2007.

Affiliated with

Also associated with

Rating

HLA-A24-binding KIF-derived peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HLA-A24-binding KIF-derived peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-A24-binding KIF-derived peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2743766